Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
Krause
G
G
Kroeger
A
A
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000009:adverse effects / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001558:Benzethonium / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D007263:Infusions, Parenteral; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000473:pathology*; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010303:Paromomycin / Q000009:adverse effects / Q000627:therapeutic use*; D017211:Treatment Failure; D014945:Wound Healing
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D001558:Benzethonium; D010303:Paromomycin; D008536:Meglumine; D000077485:Meglumine Antimoniate; C005106:methylbenzethonium chloride